Canadian biotechnology company BioAro has received the regulatory approval from the United Arab Emirates (UAE) for its Longevity+ supplement.
The supplement, designed to support healthy ageing, is part of BioAro’s expansion strategy into North America, Europe, the UK, and other regions.
BioAro’s entry into the nutraceuticals sector combines advanced research and clinical insights, showcasing its biotech origins.
Each daily dose of Longevity+ includes Nicotinamide Mononucleotide (NMN), Resveratrol, Coenzyme Q10, Curcumin, Vitamin D, and Vitamin B12.
NMN improves mitochondrial health, Resveratrol activates sirtuins, Coenzyme Q10 supports heart and energy metabolism, Curcumin is an anti-inflammatory, and Vitamins D, B12 improve neurocognitive health.
The components support cellular energy, mitochondrial health, inflammation modulation, and cognitive clarity, potentially creating synergistic effects that enhance individual benefits.
It aims to restore molecular harmony rather than overload the body with isolated nutrients.
BioAro founder Anmol Kapoor said: “We didn’t want to be just another supplement company. Our formulation was born from years of precision health research in genomics, metabolomics, and personalised medicine.
“We’ve built Longevity+ from a systems biology perspective, focusing on how molecules interact—not just how they function alone.
“We envision a future where individuals manage aging proactively, backed by data, precision, and powerful science. Longevity+ is just the beginning.”
The Longevity+ supplement line represents BioAro’s first consumer-facing health product, translating years of research into a simple daily protocol.
With regulatory clearance in the UAE, BioAro is establishing distribution partnerships in North America, Europe, the UK, India, and Southeast Asia.
The Canadian biotechnology company plans to integrate Longevity+ into its clinical programmes, offering personalised health assessments and digital wellness tracking.
Longevity+, currently under patent review, leverages BioAro’s research in nutrient absorption optimisation.
The company is planning to conduct clinical pilot studies of the supplement in Canada and the UAE, focusing on biomarker tracking to validate outcomes.
